# Tower Health Scholar Commons @ Tower Health

Reading Hospital EBP Residency

**Reading Hospital Nursing** 

2020

# Buprenorphine in Management of Neonatal Abstinence Syndrome

Melissa Braun Tower Health - Reading Hospital Department of Nursing, melissa.braun@towerhealth.org

Ariana Thomas Tower Health - Reading Hospital Department of Nursing, ariana.thomas2@towerhealth.org

Megan Hughes Tower Health - Reading Hospital Department of Nursing

Carmen Rodriguez Tower Health - Reading Hospital Department of Nursing

Abigail Lackman Tower Health - Reading Hospital Department of Nursing

Follow this and additional works at: https://scholarcommons.towerhealth.org/nrs\_ebp\_res\_read

# **Recommended Citation**

Braun, M., Thomas, A., Hughes, M., Rodriguez, C., & Lackman, A. (2020). Buprenorphine in Management of Neonatal Abstinence Syndrome. *EBP Residency* Retrieved from https://scholarcommons.towerhealth.org/ nrs\_ebp\_res\_read/1

This Poster Presentation - Tower Health Access Only is brought to you for free and open access by the Reading Hospital Nursing at Scholar Commons @ Tower Health. It has been accepted for inclusion in Reading Hospital EBP Residency by an authorized administrator of Scholar Commons @ Tower Health. For more information, please contact alexandra.short@towerhealth.org.

# Buprenorphine in the Management of Neonatal Abstinence Syndrome

Melissa Braun BSN, RN, Megan Hughes BSN, RN, Abigail Lackman RN, Carmen Rodriguez RN, and Ariana Thomas RN Maternal Child Health Division • Reading Hospital West Reading , PA Nurse Residency 2019-2020

# **Background/Problem**

Due to the opioid crisis in the United States, there has been a rise in the number of infants born with Neonatal Abstinence Syndrome (NAS). Current practice at Reading Hospital regarding treatment of NAS is based on nursing assessment of the Eat Sleep Console tool, used to determine necessary medication treatments. Morphine and clonidine are currently the standard medications used by Reading Hospital and other prominent hospitals within the region. Recent research presents buprenorphine as a more effective alternative for medication management of NAS.

# PICOT

P- Infants born to opioid addicted mothers

I- the administration of buprenorphine

- C- morphine and clonidine
- **O-** shorter length of treatment,
- decrease withdrawal symptoms

# **Practice Question**

Do infants with NAS have better outcomes (decreased length of stay, muscle rigidity, sweating, marked hyperactivity, lethargy, poor feeding, and inability to self console) with the use of buprenorphine versus the traditional pharmaceutical interventions, used at Reading Hospital, of clonidine and morphine?

## **Evidence Summary:**

Quality A

#### **Evidence Summary:**

- Meta-Analysis of RCTs 18 trials in single center studies showed reduced length of stays (2-5 days less) with buprenorphine. (Discher, et al., 2019). Level 1,
  - in utero to opioids; treatment with buprenorphine LOS 15 days vs.28 days with morphine( Kraft, Adyeniyi-Jones, et al., 2017). Level I, Quality A
- Buprenorphine length of stay was 23 days compared to 38 days for those treated with morphine (Kraft, et al., 2010). Level I, Quality B

RCT with 63 term infants exposed

Milder withdrawal symptoms in buprenorphine vs methadone with many studies (Gaalema, et al., 2011) Level I, Quality B



**Database Search Strategy** 

- PubMed
- CINAHL
- University of Pennsylvania Library

- Postnatal treatment with buprenorphine is associated with shorter length of stay, duration of treatment, and lower cumulative opioid exposure, compared with postnatal pharmacotherapy with methadone (Taleghani, et al., 2019) Level I, Quality B
- Decreased syndrome progression by 95% with buprenorphine in 19 newborns (Mizuno, et al., 2020) Level II, Quality B
- The use of sublingual buprenorphine for NAS treatment is a promising alternative strategy for reducing NAS treatment duration and cost while supporting quality care and patient safety (Hall, et. al., 2018) Level II, Quality B



## **Recommendations for Change Based on Evidence Synthesis:**

Promote the use of buprenorphine to treat neonatal abstinence syndrome by:

- Provide mothers with pamphlets about the plan of using buprenorphine to treat infant's withdrawal symptoms
- Utilize the Finnegan scoring to monitor infants' outcomes with the use of buprenorphine
- Length of stay would be documented in the patient's chart
- Mothers would be screened before giving birth to treat NAS symptoms for infants exposed to methadone

# Translation of Evidence into Practice

- To decrease the duration of opioid treatment and length of stay for NAS infants
- Improve the withdrawal symptoms for NAS
- Promoting the use of buprenorphine will help decrease the readmission rates for NAS infants

## **Evaluation of Practice** Change/Outcomes:

Although the current research available is appreciable in justifying an immediate change in practice pertaining to medication management of NAS, it does require more evidence. However, as Reading Hospital has recently adopted the Eat, Sleep Console model intended to decrease the amount of medication given to NAS infants, we should continue to monitor research on Buprenorphine to continue to expand and improve our practice. Further, as the opioid crisis continues in the United States, and the number of NAS infants born in the hospital setting is increasing, we must begin to address the stigma healthcare providers around opioid use in pregnancy. Such stigma not only reduces the likelihood for mothers to seek and engage in care, but also prevents healthcare providers from proving the most appropriate and ethical care possible.

### What are next steps

- Focusing attention toward improving the opioid crisis to reduce the number of infants born with NAS
- Further investigation and research of treatments for NAS, including Buprenorphine to assist in reducing the symptoms NAS infants experience, in turn reducing the length of hospital stay



# Keywords:

**Buprenorphine OR Morphine OR Clonidine AND Neonatal Abstinence** Syndrome OR NAS OR infant outcomes OR infant